Serum glycyl valyl-dipeptide aminopeptidase (GPDA)
Serum glycyl valine dipeptidyl aminopeptidase assay is useful for the differential diagnosis of benign and malignant liver lesions, monitoring of liver metastasis of cancer, and detection of gastric cancer, especially for alpha-fetoprotein (AFP)-negative The diagnosis of hepatocellular carcinoma and metastatic liver cancer has certain value. In patients with primary AFP who were negative and positive for serum AFP, the positive rate of elevated serum GPDA was basically the same, while the serum GPDA activity of patients with hepatic hemangioma was in the normal range. Serum GPDA decreased significantly in more than 70% of patients with gastric cancer. After gastric cancer resection, serum GPDA showed a trend of recovery. Serum GPDA assay is useful for identifying benign and malignant liver lesions, monitoring liver metastasis of cancer and detecting gastric cancer.Basic Information
Specialist classification: Oncology examination classification: biochemical examination
Applicable gender: whether men and women apply fasting: fastingAnalysis results:
In patients with intrahepatic cholestasis caused by drug-induced liver damage or primary hepatic cirrhosis, serum GPDA is significantly elevated, and serum GPDA activity in patients with acute lymphocytic leukemia, lymphosarcoma, and lymphoblastoma is significantly reduced. . Serum GPDA activity in patients with rheumatoid arthritis is slightly lower, but in severe cases, the decline is significant. Serum GPDA activity was significantly reduced in patients with systemic lupus erythematosus.
In patients with drug-induced liver damage or primary hepatic cirrhosis caused by intrahepatic cholestasis, serum GPDA was significantly elevated, and GPDA activity in urine of patients with chronic glomerulonephritis was significantly increased.
44 ~ 116U / L serum.Clinical significance
1, hepatobiliary diseases
The average activity of serum GPAD in patients with primary liver cancer was more than 2 times of the reference value of the control. The mean value of serum GPDA activity in patients with secondary liver cancer was more than 3 times of the reference value. In acute hepatitis, with or without jaundice, serum GPDA was only slightly elevated. High, and the time to return to normal is fast. The abnormal rate of chronic hepatitis or cirrhosis is lower than that of patients with acute hepatitis. The enzyme activity and abnormal rate in alcoholic hepatitis are higher than those in cirrhosis. In patients with drug-induced liver damage or primary hepatic cirrhosis caused by intrahepatic cholestasis, serum GPDA is significantly elevated, and the positive rate is also significantly higher than other liver diseases, which has certain specificity and diagnostic value.
2, gastrointestinal disease
Serum GPDA activity in patients with gastric cancer was significantly lower than that in the control group. In patients with gastroduodenal diseases with markedly reduced serum GPDA activity, the diagnosis of gastric cancer should be considered. After gastric cancer resection, the patient's serum GPDA has an upward trend.
3, other diseases
Serum GPDA activity was significantly reduced in patients with acute lymphocytic leukemia, lymphosarcoma, and lymphoblastoma. Serum GPDA activity in patients with rheumatoid arthritis is slightly lower, but in severe cases, the decline is significant. Serum GPDA activity was significantly reduced in patients with systemic lupus erythematosus.
4, urine GPDA
The activity of GPDA in urine is significantly increased in patients with chronic glomerulonephritis.Low results may be diseases: gastric cancer, acute lymphocytic leukemia, alcoholic hepatitis results may be high disease: primary liver cancer, systemic lupus erythematosus precautions
First, the precautions before blood draw
1, do not eat too greasy, high-protein food the day before the blood, to avoid heavy drinking. The alcohol content in the blood directly affects the test results.
2. After 8 pm on the day before the medical examination, you should start fasting for 12 hours to avoid affecting the test results.
3, should relax when taking blood, to avoid the contraction of blood vessels caused by fear, increase the difficulty of blood collection.
Second, should pay attention after blood draw
1. After blood is drawn, local compression is required at the pinhole for 3-5 minutes to stop bleeding. Note: Do not rub, so as not to cause subcutaneous hematoma.
2, the pressing time should be sufficient. There is a difference in clotting time for each person, and some people need a little longer to clotting. Therefore, when the surface of the skin appears to be bleeding, the compression is stopped immediately, and the blood may be infiltrated into the skin due to incomplete hemostasis. Therefore, the compression time is longer to completely stop bleeding. If there is a tendency to bleed, the compression time should be extended.
3, after the blood draw symptoms of fainting such as: dizziness, vertigo, fatigue, etc. should immediately lie down, drink a small amount of syrup, and then undergo a physical examination after the symptoms are relieved.
4. If there is localized congestion, use a warm towel after 24 hours to promote absorption.Inspection process
Take the right amount of blood and send it for inspection.
Testing instruments: automatic or semi-automatic biochemical analyzers, or automatic recording spectrophotometers with thermostats.
Detection principle: under alkaline conditions, GPDA catalyzes the hydrolysis of the substrate glycyl hydrazide p-nitroaniline to form glycyl valine and p-nitroaniline, which can cause the absorbance at 405 nm to increase, absorbance The rate of increase is directly proportional to the activity of GPDA.Not suitable for the crowd
no.Adverse reactions and risks